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Abstract
Evidence based medicine tells us that we should not accept published research at face value. Even research from established
teams published in the highest impact journals can have methodological ﬂaws, biases and limited generalisability. The critical
appraisal of research studies can seem daunting, but tools are available to make the process easier for the non-specialist.
Understanding the language and process of quality assessment is essential when considering or conducting research, and is
also valuable for all clinicians who use published research to inform their clinical practice.
We present a review written speciﬁcally for the practising geriatrician. This considers how quality is deﬁned in relation to
the methodological conduct and reporting of research. Having established why quality assessment is important, we present
and critique tools which are available to standardise quality assessment. We consider ﬁve study designs: RCTs, non-
randomised studies, observational studies, systematic reviews and diagnostic test accuracy studies. Quality assessment for
each of these study designs is illustrated with an example of published cognitive research. The practical applications of the
tools are highlighted, with guidance on their strengths and limitations. We signpost educational resources and offer speciﬁc
advice for use of these tools.
We hope that all geriatricians become comfortable with critical appraisal of published research and that use of the tools
described in this review – along with awareness of their strengths and limitations – become a part of teaching, journal clubs
and practice.
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Background
Risk of bias, allocation and randomisation describe funda-
mental aspects of clinical research, but they are only useful
if you know what they mean and how to apply them.
Understanding how to assess published research quality is
an essential skill for any clinician. For geriatricians, an ability
to evaluate the available evidence and apply the ﬁndings to
our population is essential. In this review we describe the
importance of quality assessment; outline some assessment
tools and reporting guidelines, and illustrate, with examples
from published cognitive research studies, how the use of
these tools can improve the quality of research and maxi-
mise its relevance to practice. We also highlight speciﬁc
aspects of study design and conduct which can help sup-
port the inclusion of older people in research and maximise
its value.
What is ‘quality’ in relation to research?
Quality in research includes two complementary aspects:
methodological and reporting quality. We consider both of
these aspects in turn. Here ’quality’ does not relate to the
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importance of the topic or the enjoyability of the prose.
The term is not universally popular, as some erroneously
interpret ‘quality’ as relating to the value of the research.
For brevity, and in keeping with current literature, we will
use the term in this paper. Although relevant to all branches
of medicine we highlight quality considerations for research
relevant to geriatricians (see Supplementary data, Table S1
Appendix 2, available at Age and Ageing online).
Methodological quality
Methodological quality relates to the design and conduct of
research, and is fundamental to understanding the results and
the level of conﬁdence in the ﬁndings. We consider the
important aspects of quality of conduct for each type of study.
Randomised controlled trials
A well-conducted randomised controlled trial (RCT) is con-
sidered the highest form of evidence for assessing the effect
of interventions, e.g. drug treatments [1]. In a RCT, one
group is allocated to receive an intervention and the other
receive a control. An example RCT compared the cognitive
and functional outcomes between groups given Donepezil
or placebo [2].
Assessing bias in trials
Establishing the methodological quality of individual RCTs
is largely based around assessment of the risk of bias. Bias
can be deﬁned as: ‘a systematic error, or deviation from the
truth, in results or inferences’ [3]. Recognising the import-
ance of a standardised approach to describing potential
bias, Cochrane developed a tool to assess risk of bias in
RCTs [4]. This considers bias in terms of selection, perform-
ance, detection, attrition, reporting and other biases and the user
rates studies as high, low or unclear risk of bias for each
domain [4]: these are described in detail, using the example
of a RCT of donepezil and placebo in Table 1.
Considering ‘performance bias’, ideally participants should
not be aware which arm of a study (intervention or control)
they are part of. This can be problematic for complex inter-
ventions such as falls prevention, as it can be difﬁcult to
blind patients who are receiving specialist care. This often
necessitates an assessment score of ‘high risk of bias’ when
applying the tool. However, the creating a complex ‘sham
intervention’ for the control group can have its own limita-
tions. Logan et al. describe the unintended effect of provid-
ing an activity diary to their control arm of an occupational
therapy intervention study for stroke survivors as minimis-
ing the true difference between the groups, as it stimulated
activity among controls [5].
The category of ‘other bias’ is relevant in determining
whether an RCT is valuable to practice by assessing
whether the included participants are representative of your
population. There is a recognition that many clinical trials
have excluded older people, despite the intervention being
studied being relevant to their needs [6]. Study design and
conduct can take account of the needs of this population to
increase their participation and thus the value of such trials.
Risk of bias across a group of RCTs can be summarised
graphically, generated by using the freely available ‘Review
Manager’ software (see Supplementary data, Appendix 2,
available at Age and Ageing online) [7].
Alternative approaches include scales – such as the
Jadad scale [8] – which are designed to give a summary
‘quality’ score. These can lead to an over-simpliﬁcation of
quality assessment and are at greater risk of problems with
inter-rater reliability, i.e. how different assessors respond to
the same questions and how consistently they score the
responses [9]. These scales have been criticised as, they can
result in a RCT with a single signiﬁcant ﬂaw being consid-
ered as high quality, while a RCT with a number of minor
biases would be classed as low quality. The use of quality
scores in meta-analyses of clinical trials should therefore be
avoided [10].
Non-randomised and observational studies
Non-randomised and observational studies are not inter-
changeable terms. A non-randomised interventional study
may compare the effects of an intervention (allocated in a
non-random way) with a control [11]. Observational studies
include cohort and case–control designs, and can all be
described as non-randomised. There are a variety of quality
tools for these studies, each with different indications and
applications, and with no consensus agreement on a pre-
ferred tool [12,13]. Three tools are compared in see
Supplementary data, Appendix 2, Table S3, available at Age
and Ageing online.
Non-randomised studies where an intervention is being
evaluated are primarily conducted where randomisation is
not considered to be pragmatic or possible. One example is
the Hospital Elder Life Programme, developed in the USA
as a multicomponent programme to prevent delirium [14].
Here the authors wished to study their multicomponent
intervention in one unit, compared with two control units,
but they felt that they could not feasibly randomise partici-
pants to these units due to the large numbers requiring care
in hospital [14].
Risk of bias is a key quality concern in non-randomised
studies: systematic biases may inﬂuence the outcome in non-
randomised studies, and this can be inﬂated in studies with
large sample sizes, whereas in RCTs randomisation should
minimise differences between the groups, and this is more
effective the larger the study. For example, characteristics
which might affect the incidence of delirium, such as presence
of dementia, illness severity, etc. may not be equally distribu-
ted between the groups, potentially increasing the rates of
delirium in one group compared to the other unrelated to the
intervention. The Risk of Bias Assessment tool for Non-
Randomised Studies (RoBANS) is a six-domain tool designed
to look at risk of bias alone (Table 3) [15]. RoBANS is con-
sistent with the Cochrane Risk of Bias tool [4] and thus
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simple diagrams can be created to transparently report the
assessment of each study. It has been validated by its original
authors, but has not yet had an external validation [15].
Observational studies (cohort and case–control designs)
are used where randomised trials are not feasible or ethical
or to provide initial evidence for interventions which can
later be tested in randomised trials. Cohort studies prospect-
ively follow groups who differ in their exposure to see how
this exposure relates to the development of an outcome [16].
Case–control studies retrospectively compare individuals
with a disease (‘cases’) with matched ‘controls’ without that
disease, to understand which factors are associated with the
development of the disease [16]. An example is whether
delirium is associated with development of dementia [17]. It
would be unethical, and perhaps impossible, to randomise
individuals to experience delirium, therefore a cohort study
follows individuals with and without delirium to determine
who later develops dementia. The parameters under investi-
gation are not controlled by the study design, and quality
assessment, particularly the role of bias, is crucial.
Observational studies can provide evidence of associa-
tions between factors, but they cannot prove that an
observed relationship is causative. The summary statistics
of the strength of association can be adjusted for ‘potential
confounders’ if data have been collected, such as age, sex,
disease severity [17] to check that the association which has
been observed persists after these have been accounted for.
For example, if an increased likelihood of developing
dementia after delirium is due to age differences between
the groups. However, there is always the risk of ‘residual
confounding’ – that results are due to variables that were
not included in the analyses – and future RCTs may contra-
dict the ﬁndings from observational studies.
The Newcastle-Ottawa Quality Assessment Scale (NOS)
is a freely available eight-item scale with a version for
cohort and case–control studies (Table 3) [18]. It has not
yet been published in any peer-reviewed publication. The
scale evaluates the domains of selection, comparability and
outcome or exposure. One star is allocated when a feature
of quality is present, to a maximum of nine (the compar-
ability domain can score up to two stars) [18]. No speciﬁc
value is assigned to high or low quality, although higher
scores indicate greater use of favourable methodological
aspects. The inter-rater reliability of the NOS has been
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Cochrane Risk of Bias assessment – with examples based around a randomised trial of Donepezil [2].
Form of bias & components Explanation Suggested best practice
Selection bias
Random sequence
generation
Allocation concealment
How was the sequence for determining who would be in each
group determined and how was the underlying method
concealed
Centralised electronic method, separate from the research
team so they cannot predict who will be allocated to which
group and so cannot inﬂuence those receiving a preventive
intervention
Performance bias
Blinding of participants and
personnel
How research participants or their clinical care team behave
as a result of being in a trial.
Participants and their care team should not be aware if they
are in the intervention or control group. In drug trials such
as this a placebo medication is given to those in the control
group so that individuals are not aware if they are receiving
Donepezil or not.
Detection bias
Blinding of outcome
assessment
How was the outcome of interest assessed and who
performed the assessment
Method for assessing the outcome (e.g. cognition, functional
performance etc.) should be clearly stated, using validated
tools where appropriate.Outcome assessment should be
conducted by someone who was unaware of whether
people were in the treatment or intervention group, ideally
by an independent expert.
Attrition bias
Incomplete outcome data
Is it clear how participants in the study moved through the
stages of eligibility, recruitment, allocation and follow-up?
Have individuals been lost, dropped-out of the study or
died and, if so, are the reasons for this clear and
reasonable?
Ideally this should be reported using a CONSORT ﬂow
diagram so the reader can judge the process themselves. It
is important to evaluate if losses are unevenly balanced
between groups, as this may reﬂect important effects of the
intervention which limit the generalisability to the wider
population (e.g. medication side effects/intolerance etc.)
Reporting bias
Selective reporting
Have the authors reported the outcomes included in their
study protocol.
A comprehensive study protocol is registered and accessible
to the public, e.g. on clinicaltrials.gov.
Reporting bias can occur when trial authors present additional
unplanned analyses which show favourable results (e.g. on
subgroups such as those with higher or lower MMSE scores
etc.), or do not present planned analyses. Post-hoc analyses
must be interpreted with caution as often the trial wasn’t
powered to look for these differences.
Other bias Is the result likely to be generalisable to my population?
This includes:
– Baseline imbalances between groups
– Different approaches to diagnosis from the intervention
or control
– Fraud
Successful randomisation should distribute characteristics
evenly between groups, but by chance this may not be
effective (e.g. co-morbidities such as depression may affect
cognitive function if this is more common in one group
than the other).
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questioned [19] as has its usefulness in distinguishing
between studies of high and low quality [19, 20] and its lack
of external validation makes it difﬁcult to assess this.
Diagnostic test accuracy studies
Diagnostic test accuracy studies evaluate the usefulness of a
screening or diagnostic test(s) by comparing the perform-
ance of the test(s) against an established reference standard
diagnostic approach [21]. The dementia diagnostic pathway
requires diagnostic test accuracy research as a range of
imaging tests, biomarkers, cognitive tests and informant
instruments have been advocated [22]. A recent example
featured evaluation of an informant instrument, the AD-8:
the Washington University Dementia Screening Test, to
diagnose cognitive impairment [23].
Quality assessment in test accuracy
The Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) tool is organised into four domains (patient
selection, index test, reference standard and ﬂow and timing) and,
within these there are assessments of the risk of bias and, the
applicability of ﬁndings [24]. Assessments are made for each
domain, determining yes/no/unclear for each.
In dementia test accuracy:
(i) Patient selection considers the type of people included
(e.g. cognitively intact, cognitively impaired), setting of
recruitment, exclusion criteria (particularly exclusion of
signiﬁcant co-morbidities).
(ii) Assessing applicability depends on judging how similar
they are to the population seen in practice.
(iii) The index test is whichever biomarker, imaging test, cog-
nitive or informant tool being used while the reference
standard is, for example, an expert clinical diagnosis.
(a) The index test questions ask you to judge if the
test was conducted as you would expect in practice,
if it was independent of the reference standard and
if any cut-off value was pre-speciﬁed or if these
were decided based on the results.
(b) The reference standard questions establish if the
assessment was independent from the index test
result and if the standard used is likely to correctly
identify the condition, e.g. recognised diagnostic
standard such as the International Classiﬁcation of
Disease (ICD) criteria.
(iv) Flow and timing relates to the timing of administration of
the test within the diagnostic encounter and whether all
those participating in the study are clearly accounted
for, to ensure there have been no exclusions which
might mean the tool was less useful in practice (e.g.
exclusion of those who have no carer/informant).
QUADAS-2 includes ‘signalling questions’ to help direct
the interpretation of the tool questions [24]. Some test
accuracy studies are at risk of incorporation bias as often,
particularly for cognitive and informant tests, these inform
the clinical expert diagnosis, thus studies can be penalised if
these results have formed part of the reference standard.
Graphical summary tables can be produced [24]. These
quality assessment concepts are exempliﬁed in a series of
Cochrane reviews, including use of the Informant
Questionnaire for Cognitive Decline in the Elderly
(IQCODE) in secondary care [25].
Systematic reviews and meta-analyses
Systematic reviews are the results of an organised synthesis
of the evidence on a particular topic. Meta-analyses are a
subgroup of systematic review where the same outcome
measure is reported in multiple studies and the results can
be combined statistically to calculate the estimated overall
effect size from all the trials together. A recent Cochrane
review sought to establish the evidence for the effectiveness
of case management approaches to home support for peo-
ple with dementia [26]. The outcomes which the authors
wanted to describe included institutionalisation, hospital
admission, mortality, quality of life, carer burden and ser-
vice use [26]. Meta-analysis was possible for the outcome
of institutional care, as these results were reported in eight
studies at four different time points [26].
Well-conducted systematic reviews are valuable
resources for researchers and clinicians, identifying where
sufﬁcient evidence exists for or against an intervention and
where evidence is lacking. They not only summarise the
available literature, but critically appraise it and summarise
the conﬁdence with which the conclusions are justiﬁed. If
you are planning to undertake a systematic review it is
advisable to consult your local librarian or information spe-
cialist who can provide support and expertise to help maxi-
mise the value of your work.
Assessing the quality of a systematic review
The Assessing the Methodological Quality of Systematic
Reviews (AMSTAR) tool [27] scores out of a total of 11
points. Key aspects include an a priori design, search meth-
od, quality assessment and how quality informs the review
conclusions. There is no score which separates a high from
a low quality review. AMSTAR has been validated by its ori-
ginal authors and has good inter-rater reliability and other
favourable assessment score qualities [28, 29]. Similar reli-
ability has been obtained in external validation [30].
Assessing study quality when conducting
a systematic review
It is necessary to assess the quality of the included studies in
the review, using tools speciﬁc to the study design. If a sys-
tematic review is well conducted and robust, it may be pos-
sible to make recommendations about the quality of the
identiﬁed evidence. This enables quantitative ﬁndings to be
qualiﬁed with assessment of the quality. For example, if there
are several studies of lower quality which are combined with
J. K. Harrison et al.
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one high quality RCT, the numerical results alone could lead
to erroneous conclusions to be drawn if quality is not
considered.
The Grading of Recommendations Assessment Devel-
opment and Evaluation (GRADE) system was developed
to improve the evaluation of evidence for clinical guidelines
[31], and has been widely adopted by Cochrane, the World
Health Organization and other healthcare organisations and
journals [32]. It includes a risk of bias assessment, but also
requires the assessment of consistency, indirectness, imprecision
and publication bias [31].
• Consistency indicates whether the ﬁndings are consistent
with those in the other included studies
• Indirectness indicates whether the evidence is applicable to
the entire population or whether it is indirect and only
applicable to a sub-set, e.g. exclusion of those with other
signiﬁcant co-morbidities such as depression would lead
you to conclude a dementia research study was at risk of
indirectness.
• Imprecision indicates the conﬁdence interval associated with
a ﬁnding, this will largely be reduced by studies with larger
sample sizes, although not if the studies produce conﬂict-
ing results.
• Publication bias can occur if not all studies conducted in
the ﬁeld are published and available for inclusion.
Typically this occurs when studies with a negative result
are not published, leading to a summary estimate of posi-
tive results which may be biased in this direction. This is
more common in studies of interventions and can only be
formally assessed where data are available for direct com-
parisons between studies.
It is possible to assess the quality of each ﬁnding from a
systematic review by applying GRADE, allowing you to
present the statistical ﬁndings from each result alongside an
assessment of the quality of the evidence from which the
result is derived, transparently accounting for why evidence
has been downgraded. Its use is not limited to RCTs, but
many of the parameters can only be assessed using
quantitative data and downgrading is required for study
designs other than RCTs. As a system GRADE lends itself
well to identifying areas for which further research evidence
is required to improve the quality of the evidence. The
GRADEpro software to create accompanying tables of
results is also freely available (Figure 1) [33].
Reporting quality
Reporting quality describes how well a piece of scientiﬁc
work is written- as an article published by a scientiﬁc journal.
A key criterion is whether the study as reported would allow
a reader to replicate the work. Poor quality of reporting is
common [34, 35], which can make it difﬁcult to assess the
methodology [35]. Various approaches to improving the qual-
ity of scientiﬁc reporting have been proposed. Successful
examples include the guidance offered by Cochrane for sys-
tematic review [36] and the Enhancing the QUAlity and
Transparency Of health Research (EQUATOR) Network.
The EQUATOR Network provides resources for authors,
editors and educationalists to promote all aspects of improv-
ing reporting quality in health research (Figure 1) [37,38].
Reporting guidance is presented in the form of a check-
list of recommendations speciﬁc for the study design. The
EQUATOR website includes a tool to assist in the selection
of the correct guideline [39], as it can sometimes be difﬁcult
for researchers to be conﬁdent which is the most appropri-
ate. The ﬁrst of these guidelines was the Consolidated
Standards of Reporting Trials (CONSORT) Statement for
RCTs [40]. CONSORT now comprises a 22-item checklist
assessing each section of the research paper [41].
CONSORT recommends the use of a structured ﬂow dia-
gram: describing numbers of participants at enrolment, allo-
cation, follow-up and analysis [42]. Similar guidelines exist
for the reporting of other study designs [39] and we
encourage all authors to use these.
In reporting guidelines individual items are not weighted
to indicate the quality the study report (and the completion of
most or all items on the checklist is not necessarily an
• EQUATOR Checklists & Guidance for reporng studies: 
hp://www.equator-network.org/
• Cochrane Handbook for Systemac Reviews of Intervenons: 
hp://handbook.cochrane.org/
• Cochrane Handbook for Diagnosc Test Accuracy Reviews: 
hp://dta.cochrane.org/handbook-dta-reviews
• Crical Appraisal Skills Programme Resources and Checklists for each study design: 
hp://www.casp-uk.net/
• BMJ series on crical appraisal: hp://www.bmj.com/about-bmj/resources-
readers/publicaons/how-read-paper
• Greenhalgh T. How to Read a Paper. 5th Ed. 2014. Wiley Blackwell. BMJ Books
• GRADEpro soware to generate summary of ﬁndings tables: 
hp://www.guidelinedevelopment.org/
• Review Manager (to generate Risk of Bias tables and other ﬁgures): 
hp://tech.cochrane.org/revman
Figure 1. Useful links to resources for quality assessment and reporting of studies.
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indicator of quality). For example, in Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE), one item is ‘indicate the study’s design with a
commonly used term in the title or abstract’ and another is
‘describe any efforts to assess potential sources of bias’ [43].
Clearly, a lack of consideration of bias will have a major
impact on the results, whereas the title of the paper will not.
Note that these are assessments of reporting quality, not an
assessment of the methodology of the study itself.
Are quality tools valuable?
Quality tools are widely available, but not universally accepted.
Their use has improved the quality of reporting of studies
[44, 45] with greater improvements in journals which promote
or require their use [46, 47] and they can be useful for peer
reviewers. Possible arguments against their use include the
over-standardisation of published material. It can also challenge
researchers if they do not have all the required information
Another limitation for some tools is their lack of exter-
nal validation. Tool authors must seek external usage and
testing of their tool to fully understand how it is applied by
non-specialists. In particular identifying questions which
may be open to interpretation can allow guidance notes to
be provided.
How and when to use the tools
Critical appraisal for journal clubs, peer review
or clinical use
For those delivering teaching about the principles of meth-
odological quality assessment or running local journal clubs,
there are plenty of resources available. ‘How to Read a
Paper’ [48] is a short and accessible read and the Critical
Appraisal Skills Programme Checklists [49] can be helpful
for facilitating group sessions. Their 10–12 question check-
lists cover each of the key study designs. These are typically
divided into three sections with prompts beside each ques-
tion to help understanding [49]. They are largely designed
to familiarise users with study designs and help them evalu-
ate the relevance of the paper to their practice as they con-
tain several subjective elements which may not lend
themselves to incorporation in a formal quality assessment.
Alternatively, the components of other methodological
quality assessment tools can be used to facilitate discussion.
Research study design
If you are at the beginning of a project, the tools can help
identify factors to include in your design (e.g. who will
assess your outcome and how can they be blinded to which
participants have received the intervention). Similarly, if you
are planning a systematic review, the reporting tools prompt
you to ﬁnd a second reviewer to improve the quality of
your data. You also need to decide which tool to use to
assess the methodological quality of the studies included in
your review – be aware of their strengths and limitations.
Research study reporting
Reporting quality checklists can help you structure the write
up of your study, ensuring you present all recommended
information. It is also important to be aware that many jour-
nals require that a completed checklist is submitted with your
manuscript, indicating where you have addressed each point.
Conclusions
Understanding and evaluating the evidence behind clinical
practice is a valuable skill for any geriatrician. The formal
tools which have been developed for assessment of meth-
odological and reporting quality can be helpful when evalu-
ating evidence or planning writing. Quality assessment is
difﬁcult and the most honest way to appraise studies is to
look at the individual components of quality, rather than
attempting a binary categorisation into high or low quality.
These can then be presented in a transparent and under-
standable way, allowing you to determine whether the
research is applicable to your clinical practice.
Key points
• Evaluating how well a study has been conducted is essen-
tial to determine if the ﬁndings are relevant to clinical
practice.
• Making this assessment can be difﬁcult depending on
how well a study is reported.
• Guidelines are available to help assess the quality of a
study’s methods and to guide study reporting.
• These guidelines are useful for all clinicians wishing to
critically appraise research ﬁndings for application in
practice.
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